Annual Accounts and Directors' Report

The report describes the Group's 2018 consolidated revenue of 303,203 thousand euros and year-end headcount of 1,224 employees. It highlights continued pharmaceutical and R&D activity, including the enoxaparin biosimilar and ISM technology platform. Environmentally, the Group reports ISO14001:2015 certification for three companies and monitors energy, water, waste, and emissions across its operations. The consolidated non-financial information statement was independently verified by KPMG Asesores, S.L. on a limited-assurance basis.